Read More

Celldex Announces Acceptance Of Abstract For Barzolvolimab Phase 1b Results In Chronic Spontaneous Urticaria For Late-Breaking Presentation At The European Academy Of Allergy And Clinical Immunology (EAACI) Annual Congress 2022

Celldex Announces Acceptance of Abstract for Barzolvolimab Phase 1b Results in Chronic Spontaneous Urticaria for Late-Breaking Presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Annual

CLDX